Weekly Digest – October 2026 Weekly Digest – October 2026 22 October 2026: BioNTech and Gilead partner to evaluate Pumitamig plus Trodelvy in 1L TNBC BioNTech announced a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate pumitamig […]
Weekly Digest – October 2026 Weekly Digest – October 2026 27 October 2026: NMPA accepted the new indication application for sac-TMT plus pembrolizumab as 1L treatment for PD-L1-negative non-squamous NSCLC Kelun-Biotech announced that China’s NMPA has accepted for review a […]
Weekly Digest – October 2026 Weekly Digest – October 2026 22 October 2026: BioNTech and Gilead partner to evaluate Pumitamig plus Trodelvy in 1L TNBC BioNTech announced a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate pumitamig […]
Weekly Digest – October 2026 Weekly Digest – October 2026 26 October 2026: VitsGen Therapeutics receives FDA ODD for FAP-Targeted Radiopharmaceutical 177Lu-FAP-VG11 VitsGen Therapeutics announced that the U.S. FDA has granted Orphan Drug Designation to 177Lu-FAP-VG11 for the treatment of […]
Weekly Digest – October 2026 Weekly Digest – October 2026 27 October 2026: AimedBio and Boehringer Ingelheim initiate Phase 1 study of ADC BI 4060107 AimedBio and Boehringer Ingelheim announced that the first patient has been dosed in the phase […]
Weekly Digest – October 2026 Weekly Digest – October 2026 26 October 2026: Xilio Therapeutics dosed the first patient in the Phase 1/2 trial of XTX501 for metastatic NSCLC Xilio Therapeutics has dosed the first patient in a phase 1/2 […]
